Anti-CSCL1/ ™EM63A/ KIAA0792 monoclonal antibody

Anti-CSCL1/ ™EM63A/ KIAA0792 antibody for FACS & in-vivo assay

Target products collectionGo to ™EM63A/™EM63A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1837-Ab-1/ GM-Tg-hg-MP1837-Ab-2Anti-Human ™EM63A monoclonal antibodyHuman
GM-Tg-rg-MP1837-Ab-1/ GM-Tg-rg-MP1837-Ab-2Anti-Rat ™EM63A monoclonal antibodyRat
GM-Tg-mg-MP1837-Ab-1/ GM-Tg-mg-MP1837-Ab-2Anti-Mouse ™EM63A monoclonal antibodyMouse
GM-Tg-cynog-MP1837-Ab-1/ GM-Tg-cynog-MP1837-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM63A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1837-Ab-1/ GM-Tg-felg-MP1837-Ab-2Anti-Feline ™EM63A monoclonal antibodyFeline
GM-Tg-cang-MP1837-Ab-1/ GM-Tg-cang-MP1837-Ab-2Anti-Canine ™EM63A monoclonal antibodyCanine
GM-Tg-bovg-MP1837-Ab-1/ GM-Tg-bovg-MP1837-Ab-2Anti-Bovine ™EM63A monoclonal antibodyBovine
GM-Tg-equg-MP1837-Ab-1/ GM-Tg-equg-MP1837-Ab-2Anti-Equine ™EM63A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1837-Ab-1/ GM-Tg-hg-MP1837-Ab-2; GM-Tg-rg-MP1837-Ab-1/ GM-Tg-rg-MP1837-Ab-2;
GM-Tg-mg-MP1837-Ab-1/ GM-Tg-mg-MP1837-Ab-2; GM-Tg-cynog-MP1837-Ab-1/ GM-Tg-cynog-MP1837-Ab-2;
GM-Tg-felg-MP1837-Ab-1/ GM-Tg-felg-MP1837-Ab-2; GM-Tg-cang-MP1837-Ab-1/ GM-Tg-cang-MP1837-Ab-2;
GM-Tg-bovg-MP1837-Ab-1/ GM-Tg-bovg-MP1837-Ab-2; GM-Tg-equg-MP1837-Ab-1/ GM-Tg-equg-MP1837-Ab-2
Products NameAnti-™EM63A monoclonal antibody
Formatmab
Target Name™EM63A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-™EM63A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CSCL1/ ™EM63A/ KIAA0792 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1837
    Target Name™EM63A
    Gene ID9725,208795,289318,701499,490389,101085772,534017,100057436
    Gene Symbol and SynonymsHLD19,KIAA0792,RGD1306829,Tmem6,™EM63A,Tmem64a
    Uniprot AccessionO94886
    Uniprot Entry NameCSCL1_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000196187
    Target ClassificationIon Channel

    The target: ™EM63A, gene name: ™EM63A, also named as KIAA0792. Enables mechanosensitive ion channel activity. Predicted to be involved in cation transmembrane transport. Located in centriolar satellite and lysosomal membrane. Implicated in hypomyelinating leukodystrophy. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.